Premium
Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial
Author(s) -
Schwartz Peter E.,
Chambers Joseph T.,
Kohorn Ernest I.,
Chambers Setsuko K.,
Weitzman Hervey,
Voynick Irene M.,
Maclusky Neil,
Naftolin Frederick
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890315)63:6<1074::aid-cncr2820630606>3.0.co;2-0
Subject(s) - medicine , tamoxifen , chemotherapy , oncology , ovarian cancer , progestin , estrogen receptor , estrogen , antiestrogen , cytotoxic t cell , breast cancer , prospective cohort study , doxorubicin , randomized controlled trial , cancer , gynecology , biology , in vitro , biochemistry
One hundred patients with Stage III and IV epithelial ovarian cancer participated in a prospective randomized study to determine whether the addition of tamoxifen, an estrogen agonist‐antagonist, to standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum) would significantly improve survival. Fifty‐one patients received the standard cytotoxic chemotherapy and 49 received tamoxifen as well. No significant difference in overall or progression‐free survival between these two patient groups was observed. Cytosol steroid receptor determinations were performed on tumor samples from 72 patients. No correlation was evident between therapy and cytosol estrogen and progestin receptor content of the tumors. This study suggests that the strategy of combining an antiproliferative, hormonally active agent with cytotoxic chemotherapy for management of advanced ovarian cancer may be inappropriate.